Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89
HOS-110685 · Präparat HOS-093385
Increased systemic exposure to didanosine may increase didanosine related adverse reactions. Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported. Co-administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine. A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV-1 infection. Adefovir dipivoxil AUC: ↔ Tenofovir disoproxil should Cmax: ↔ not be administered concurrently with adefovir dipivoxil (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): adefovir dipivoxil (HOS-110478) adefovir (HOS-088122) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage b4035cc09b12c98ac133957e78b020324d3da278f1fba45750e18dfd4ac109bb · Zeichen 5964–8763 im Abschnitt